Esteve Pharmaceuticals has acquired the exclusive rights to market Inbrija dry powder levodopa in Spain and expects to launch the product there by the end of 2022, according to Acorda Therapeutics. Esteve will pay Acorda "a significant double-digit percent of the selling price" for Acorda to supply the product. The Inbrija DPI was approved in Europe for the … [Read more...] about Esteve Pharmaceuticals to market Inbrija levodopa DPI in Spain
Business
Celltrion, Inhalon partner on inhaled regdanvimab for COVID-19
Inhalon Biopharma has announced that it is partnered with Celltrion to develop a nebulized formulation of regdanvimab, a monoclonal antibody for the treatment of COVID-19, which will be known as IN-006. In May 2021, Inhalon announced that it had been awarded a US Army contract worth $7 million for development of IN-006. The company says that a Phase 1 study of IN-006 … [Read more...] about Celltrion, Inhalon partner on inhaled regdanvimab for COVID-19
Leyden Labs partners with Nanopharm on antiviral nasal spray development
OINDP research and development specialist Nanopharm has partnered with Leyden Labs for development of Leyden Labs antiviral nasal spray candidates, the companies have announced. Nanopharm, which was acquired by Aptar Pharma in 2019, will develop a liquid nasal formulation in preparation for Phase 1 trials and may evaluate a powder formulation as well. In March 2021, … [Read more...] about Leyden Labs partners with Nanopharm on antiviral nasal spray development
Philip Morris announces £1 billion offer for Vectura
Philip Morris International (PMI) has announced an offer of ~£1.05 billion for the acquisition of inhalation CDMO Vectura. In May 2021, Vectura announced that it would be acquired by the Carlyle Group for £958 million. The Vectura Board has withdrawn its support for the Carlyle deal and agreed to the PMI acquisition, citing PMI's experience with aerosol delivery among … [Read more...] about Philip Morris announces £1 billion offer for Vectura
Rokote Labs gets €9 million for development of intranasal COVID vaccine
Rokote Laboratories, a spin out from the University of Helsinki and the University of Eastern Finland, has raised €9 million for development of an intranasal vaccine against the SARS-CoV-2 virus, the universities have announced. The funding, which includes €3.5 million from the Finnish Cultural Foundation, Ferring Ventures SA, and the Jenny and Antti Wihuri … [Read more...] about Rokote Labs gets €9 million for development of intranasal COVID vaccine
PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI
Dutch DPI developer Pure IMS has announced a new partnership with CDMO Sever Pharma Solutions (formerly Disphar International) and Radboud University Medical Center (Radboudumc) for development of a tigecycline dry powder inhaler for the treatment of multi-drug resistant Mycobacterium abscessus lung infections. Radboudumc research has demonstrated that inhaled … [Read more...] about PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI
M8 Pharmaceuticals gets Brazilian and Mexican rights to Marinomed’s Carragelose nasal spray
M8 Pharmaceuticals said that it has acquired exclusive rights to market Marinomed's Carragelose nasal spray in Brazil and Mexico. The company will market the product in those countries as Barlo nasal spray for the prevention of respiratory viruses. Carragelose nasal sprays are currently marketed over 40 countries, including Italy, Austria, Canada, China, and … [Read more...] about M8 Pharmaceuticals gets Brazilian and Mexican rights to Marinomed’s Carragelose nasal spray
FluGen gets funding from US Department of Defense for intranasal flu vaccine
FluGen said that it has received an $11.4 million grant from the United States Department of Defense for a Phase 1b study to evaluate the ability of its M2SR intranasal flu vaccine to protect against a variety of flu strains, including those like H3N2 that are mismatched to current vaccines. In February 2019, FluGen announced that a Phase 2 trial of the M2SR vaccine … [Read more...] about FluGen gets funding from US Department of Defense for intranasal flu vaccine
Altimmune halts development of AdCOVID intranasal vaccine, terminates trial of T-COVID intranasal therapeutic
Altimmune has discontinued development of its AdCOVID intranasal vaccine for the prevention of COVID-19 after the failure of a Phase 1 trial and has stopped enrollment in a Phase 1/2 trial of its T-COVID intranasal therapy for COVID-19 the company said. The FDA had cleared the IND for the Phase 1 trial of AdCOVID in February 2021; the Phase 1/2 trial of T-COVID was … [Read more...] about Altimmune halts development of AdCOVID intranasal vaccine, terminates trial of T-COVID intranasal therapeutic
Pieris announces development of inhaled anticalin for IPF, long COVID
Pieris Pharmaceuticals has announced that it will develop an inhaled anticalin known as PRS-220 for the treatment of idiopathic pulmonary fibrosis and for pulmonary fibrosis following COVID infection, with both programs slated to start in 2022. A €14.2 million grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy will fund development … [Read more...] about Pieris announces development of inhaled anticalin for IPF, long COVID